207798-38-7

Basic information

• Product Name: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;tert-butyl 4-(4-forMylphenoxy)piperidine-1-carboxylate
• CAS NO: 207798-38-7
• Molecular Formula: C₁₇H₂₃NO₄
• Molecular Weight: 305.36900
• Mol File: 207798-38-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(207798-38-7)
• EPA Substance Registry System: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(207798-38-7)

Safety Data

• Hazardous Substances Data: 207798-38-7(Hazardous Substances Data)

Usage

General Description

The chemical 4-(4-Formyl-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester is a compound with a molecular formula of C18H23NO5. It is typically used as a building block in organic synthesis and pharmaceutical research. The tert-butyl ester group allows for increased stability and solubility of the compound, making it useful for various applications in the chemistry and pharmaceutical industries. This chemical may have potential uses in drug development and can serve as a precursor for the synthesis of various bioactive molecules.

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 10465-78-8 diamide 
• 4143-61-7 diethyl diazodicarboxylate 
• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 
• 118811-07-7 tert-butyl 4-(tosyloxy)piperidin-1-carboxylate 

Downstream Products

• 1190979-26-0 N-tert-butyl 4-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenoxy)piperidine-1-carboxylate 
• 943636-92-8 C₂₂H₂₇FN₂O₄ 
• 1404098-16-3 2-(4-(4-((2,4,6-trioxotetrahydropyrimidin-5(6H)-ylidene)-methyl)phenoxy)piperidin-1-yl)nicotinonitrile 
• 1404098-17-4 5-(4-(1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-4-yloxy)-benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione 
• 1404098-31-2 5-(4-(1-(5-methylpyrazine-2-carbonyl)piperidin-4-yloxy)benzylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione 
• 1404098-32-3 5-(4-(1-(4-chloro-2-methoxybenzoyl)piperidin-4-yloxy)benzylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione 
• 1404098-33-4 5-(4-(1-(4-fluorophenylsulfonyl)piperidin-4-yloxy)benzylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione 
• 321337-38-6 tert-butyl 4-(4-(hydroxymethyl)phenoxy)piperidine-1-carboxylate 
• 1404098-15-2 5-(4-(1-(5-nitropyridin-2-yl)piperidin-4-yloxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione 
• 1404098-13-0 5-(4-(1-(4-nitropyridin-2-yl)piperidin-4-yloxy)benzylidene)-pyrimidine-2,4,6(1H,3H,5H)-trione 

Relevant articles and documents

8-substituted styryl xanthine derivative and application thereof

The invention discloses an 8-substituted styryl xanthine derivative and application thereof, and particularly relates to a novel 8-substituted styryl xanthine derivative and a pharmaceutical composition containing the compound which can be used as a selective adenosine A2A receptor antagonist. The invention also relates to a method for preparing the compound and the pharmaceutical composition, andapplication of the compound and the pharmaceutical composition in preparation of drugs for treating adenosine A2A receptor related diseases, especially Parkinson's disease.

Design, synthesis, and biological evaluation of 5-aminotetrahydroquinoline-based LSD1 inhibitors acting on Asp375

The abnormal expression of lysine-specific histone demethylase 1 (LSD1) is associated with different cancer types, and LSD1?inhibitory activity seems to have high therapeutic potential in cancer treatment. Here, we report the design, synthesis, and biochemical evaluation of novel 5-aminotetrahydroquinoline-based LSD1 inhibitors. Among them, compounds A6, A8, B1–B5, and C4 showed preferable inhibitory effects on LSD1, with IC50 = 0.19–0.82 μM. Several potent compounds were selected to evaluate their antiproliferative activity on A549 cells and MCF-7 cells with a high expression of LSD1. The potential binding modes of the compounds were revealed through molecular docking to rationalize the potency of compounds toward LSD1. Our data recognized that the 5-aminotetrahydroquinoline scaffold may serve as a starting point for developing potent LSD1 inhibitors for cancer therapy.

Tetrahydroquinoline derivative as well as preparation method and application thereof

The invention belongs to the field of drug synthesis, and provides a tetrahydroquinoline derivative shown as a general formula (I) and pharmaceutically acceptable salt, stereoisomers or prodrugs thereof, in which A, Ra, Rb, n, m and R are as described in

Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors

The targeted regulation of LSD1, which is highly expressed in a variety of tumor cells, is a promising cancer therapy strategy. Several LSD1 inhibitors are currently under clinical evaluation, and most of these inhibitors are irreversible. Here, we report the design, synthesis and biochemical evaluation of novel tetrahydroquinoline-based reversible LSD1 inhibitors. Compounds 18s and 18x, which are selective to LSD1 over MAO-A/B, exhibit excellent LSD1 inhibition at the molecular levels with IC50 = 55 nM and 540 nM, respectively. The classic Lineweaver–Burk plots revealed that compound 18s could reversibly bind the LSD1 enzyme in a noncompetitive manner. Molecular docking was used to reveal the potential binding-mode of the compounds and interpret the structure-activity relationships. Furthermore, compounds 18s and 18x significantly inhibited proliferation (IC50 = 1.13 μM and 1.15 μM, respectively) and induced apoptosis in MGC-803 cells with high expression of LSD1. Compound 18x showed acceptable liver microsomal stability. Meanwhile, 18x did not appear to inhibit CYPs at 10 μM in vitro. Remarkably, the oral administration of compound 18x can inhibit the growth of MGC-803 xenograft tumors without significant side effects. Our findings suggest that tetrahydroquinoline-based LSD1 inhibitors deserve further investigation for the treatment of LSD1 overexpressing cancer.

Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity Relationship

The balance of methylation levels at histone H3 lysine 4 (H3K4) is regulated by KDM1A (LSD1). KDM1A is overexpressed in several tumor types, thus representing an emerging target for the development of novel cancer therapeutics. We have previously describe

Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties

A novel series of melanin concentrating hormone receptor 1 (MCHr1) antagonists were the starting point for a drug discovery program that culminated in the discovery of 103 (AZD1979). The lead optimization program was conducted with a focus on reducing lipophilicity and understanding the physicochemical properties governing CNS exposure and undesired off-target pharmacology such as hERG interactions. An integrated approach was taken where the key assay was ex vivo receptor occupancy in mice. The candidate compound 103 displayed appropriate lipophilicity for a CNS indication and showed excellent permeability with no efflux. Preclinical GLP toxicology and safety pharmacology studies were without major findings and 103 was taken into clinical trials.

MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS

The present invention relates to compounds compound according to Formula (III); and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have D2receptor antagonist/(partial) agonist effects and H3antagonistic effects, pharmaceutical compositions thereof, and methods of using them for application in the prophylaxis or treatment of CNS disorders.

ACRYLAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS

The present invention relates to novel acrylamide compounds of formula (I), and their pharmaceutically acceptable salts and process of their preparation. (The chemical formula should be inserted here.) The compounds of formula (I) are useful in the treatment of various disorders that related to Histamine H3 receptors.

IMIDAZO [4, 5 - B] PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.

Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H, 5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD), one of chronic liver diseases, seems to be rising as the obesity epidemic continues. In this study, 54 novel (thio)barbituric acid derivatives have been synthesized and evaluated for pharmacological activity. 7h exhibited potent glucose-lowering effects on insulin-resistant HepG2 cells and regulated adiponectin and leptin expression in 3T3-L1 adipocytes. Oral administration of 7h at 25 mg kg-1 day -1 for 4 weeks improved the progression of high fat diet-induced NAFLD by reducing the weight of body, liver, and fat, as well as modulating serum levels of fasting glucose, insulin, triglycerides, LDL-c, ALT, adiponectin and hepatic contents of triglycerides, total cholesterol. H&E stainings revealed that 7h blocked fat deposition in liver and the increase of adipocyte number and size in adipose tissues from NAFLD. Furthermore, treatment with 7h alleviated the obese clinical symptoms, recovered serum biomarkers to appropriate ranges, and improved glucose tolerance by OGTT and IGTT in DIO mice.